|
Trinity Medical Group USA |
|
|
Silom Soi 7, Silom Road
Bangkok, Thailand 10500 USA
phone:(66-2) 2315322
fax:(662) 636-6888
|
|
| Symbol |
TMGU |
| Exchange |
OTC |
| Founded |
1995 |
| Employees |
3 |
|
|
| www.trinitycorp.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| The Trinity Medical Group was established to sponsor the REMUNEr, a candidate therapeutic vaccine for AIDS. |
|
| Management |
| Arun Churdboonchart, Chairman of the Board Vina Churdboonchart, President, Director Elizabeth Namnath, Secretary James S. Namnath, Chief Executive Officer, Director Gary E. Wilson, Chief Financial Officer, Executive Vice President-Finance, Treasurer |
| |
|
|
|
|
|
|
|
| Keywords |
| aids, virus, hiv, HIVAIDS |
|
|
|
| Description |
|
The Trinity Medical Group was set up to sponsor the REMUNEĈ vaccine clinical trial in Thailand organized by Mahidol University. REMUNEĈ, a candidate therapeutic vaccine for AIDS, is developed by The Immune Response Corporation (IRC) of San Diego, California, USA |
|
| Products / Services |
REMUNE may work with currently available antiviral drugs (AZT, ddI, ddC, and protease inhibitors) as a complementary treatment for HIV infection. The Company believes that while antiviral drugs interrupt the reproduction process of HIV within infected cells, REMUNE stimulates the immune systems to destroy HIV-infected cells.
|
|
| Technology / Differentiation |
| REMUNE is derived from Zairian HIV-1 strain HZ-321, composed of gp120-depleted HIV-1 propagated in HUT-78 cells and inactivated in beta-propriolactone and irradiation. The inactivated material is emulsified with mineral oil (Incomplete Freund's Adjuvant) at 1:1 ratio. Each 1 ml dose (at least 100μg or 10 units) has viral protein and p24. Administration of inactivated virus may stimulate cellular immune responses, which may slow the replication of HIV-1 through increased immunologic control over infected cells or other as yet undetermined mechanisms. The use of inactivated virus could theoretically stimulate broader immune responses that are capable of suppressing more diverse strains of HIV than vaccines based on sub-units of the virus. |
|
| Market / Customers |
Aids Patients
|
|
| Status |
| In Thailand, the results of REMUNE clinical trials showed that it is safe and well tolerated. No serious adverse events were reported during the conduct of the studies. The use of REMUNE in HIV infected Thai patients sustains or increases CD4+ cell counts thus delaying the use of antiretroviral drugs. Further, the genotypic drug-resistance study done in volunteers showed no drug mutation in REMUNE treated group, thereby delaying the progression of HIV infection to AIDS. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
